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Abstract
Background: WNT7a, a member of the Wnt ligand family implicated in several developmental processes, has also
been reported to be dysregulated in some types of tumors; however, its function and implication in oncogenesis is
poorly understood. Moreover, the expression of this gene and the role that it plays in the biology of blood cells remains
unclear. In addition to determining the expression of the WNT7A gene in blood cells, in leukemia-derived cell lines, and
in samples of patients with leukemia, the aim of this study was to seek the effect of this gene in proliferation.
Methods: We analyzed peripheral blood mononuclear cells, sorted CD3 and CD19 cells, four leukemia-derived cell
lines, and blood samples from 14 patients with Acute lymphoblastic leukemia (ALL), and 19 clinically healthy subjects.
Reverse transcription followed by quantitative Real-time Polymerase chain reaction (qRT-PCR) analysis were
performed to determine relative WNT7A expression. Restoration of WNT7a was done employing a lentiviral system
and by using a recombinant human protein. Cell proliferation was measured by addition of WST-1 to cell cultures.
Results: WNT7a is mainly produced by CD3 T-lymphocytes, its expression decreases upon activation, and it is severely
reduced in leukemia-derived cell lines, as well as in the blood samples of patients with ALL when compared with
healthy controls (p ≤0.001). By restoring WNT7A expression in leukemia-derived cells, we were able to demonstrate that
WNT7a inhibits cell growth. A similar effect was observed when a recombinant human WNT7a protein was used.
Interestingly, restoration of WNT7A expression in Jurkat cells did not activate the canonical Wnt/b-catenin pathway.
Conclusions: To our knowledge, this is the first report evidencing quantitatively decreased WNT7A levels in
leukemia-derived cells and that WNT7A restoration in T-lymphocytes inhibits cell proliferation. In addition, our
results also support the possible function of WNT7A as a tumor suppressor gene as well as a therapeutic tool.
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Background
The Wnt signaling pathway describes a complex network
of proteins involved in differentiation, proliferation, migra-
tion, and cell polarity, which play important roles during
embryonic development, tissue regeneration, and in
homeostatic mechanisms [1,2]. Wnt molecules are a highly
conserved group of secreted cysteine-rich lipoglycoproteins
that work as signaling molecules. Nineteen different Wnt
family members have been described in humans to date.
T h eb i n d i n go ft h e s el i g a n ds to its receptor complex
(Frizzled/LRP-5/6) leads to activation of the pathway [1,3].
Distinct sets of Wnt and Frizzled ligand-receptor pairs can
activate different pathways and lead to unique cellular
response [3,4]. Wnt signals are transduced through at least
three different intracellular pathways: Wnt/b-catenin, also
known as canonical pathway; Wnt/Ca++, and the Planar
cell polarity (Wnt/JNK) pathway [1,3,5]. In the canonical
pathway, receptor activation leads to stabilization of
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Glycogen synthase kinase (GSK)-3b.U n p h o s p h o r y l a t e d
b-catenin accumulates in the cytoplasm and then translo-
cates into the nucleus, activating target gene expression
through a complex network of co-receptors (TCF/LEF
transcription factors) and repressors (Groucho) [6-8]. The
Wnt/b-catenin pathway is involved in the self-renewal and
proliferation of hematopoietic stem cells and has been also
implicated in numerous types of cancers [7,9,10]. Dysregu-
lation of this pathway is a hallmark of several types of
tumors [7,11-13].
Leukemic cells are highly heterogeneous, and their
mechanisms of tumorigenesis are poorly understood.
Recently, dysregulation of the Wnt signaling pathway
has been implicated in the pathogenesis of some leuke-
mia types [14-17]. Moreover, different expression pro-
files of some WNT genes and their related signaling
molecules have been reported in hematological cancers
[12,18-22]. However, there are limited numbers of stu-
dies regarding the role of WNT7a, both in normal and
in leukemia-derived cells [19,23,24].
Because our group has observed strongly decreased
expression of WNT7A in different tumor-derived cell
lines (unpublished data), we have focused our attention
on the expression of WNT7A in normal peripheral
blood cells, in leukemia-derived cell lines, and in
patients with Acute lymphoblastic leukemia (ALL).
Methods
Ethics statement
Fourteen peripheral blood samples from patients with
leukemia were collected from the Hospital Civil Fray
Antonio Alcalde and blood samples from healthy volun-
teers at the Instituto Mexicano del Seguro Social (IMSS)
Blood Bank after approval by the Ethical and Research
Committee No. 1305 of the Centro de Investigación
B i o m é d i c ad eO c c i d e n t e( C I B O )-I M S S( p r o j e c t
approval numbers 1305-2006-07 and 1305-2010-2).
Written informed consent from patients and healthy
volunteers (following local Ethics Committee guidelines
and international norms) was also required prior to
blood sample collection.
Cell line culture
The human leukemia-derived cell lines Jurkat, K562,
CEM, HL60, and the BJAB cells (lymphoma-derived B
cells) were used as study model. Jurkat and CEM pos-
sess a lymphoblastic phenotype, whereas K562 and
HL60 have a myeloid origin. Cells were cultured in
RPMI-1640 medium supplemented with 10% Fetal
bovine serum (FBS), penicillin (100 U/mL), and strepto-
mycin (100 μg/mL) at 37°C in a humidified atmosphere
of 5% CO2. All products mentioned previously were
obtained from the GIBCO™ Invitrogen Corporation.
Sorting of CD3- and CD19-positive cells
Peripheral blood mononuclear cells (PBMC) obtained
from five healthy volunteers (12 mL of peripheral blood)
were isolated by density-gradient centrifugation with
Ficoll-Paque™ PLUS (GE Healthcare). PBMC included
lymphocytes, monocytes, macrophages, NK cells, and
also basophils and dendritic cells. These cells can be
extracted from whole blood using Ficoll, which separates
the blood into a top layer of plasma, followed by a layer
of PBMC and a bottom fraction of polymorphonuclear
cells and erythrocytes. The PBMC were resuspended in
PBS and stained with an anti-CD3 antibody (sc-1179-
FITC, Santa Cruz Biotechnology) to select T-lympho-
cytes and with an anti-CD19 antibody (sc-19650-PE,
Santa Cruz Biotechnology) to select B-lymphocytes.
After incubation with both antibodies, cells were washed
and positive cells for CD3 or CD19 were sorted on a
FACSAria (Becton Dickinson).
RNA isolation
Leukemia-derived cell lines were seeded at a density of
5×1 0
6 in 75-cm
3 flasks and harvested after 24 h for
Total RNA extraction by using the PureLink™ Micro-
to-Midi Total RNA Purification System (cat. no. 12183-
018, Invitrogen) as described by the manufacturers.
RNA from PBMC, CD3
+ and CD19
+cells was also
extracted from five healthy volunteers by this method
and put together to create a representative sample
group of each cell type for the qRT-PCR analysis.
Peripheral blood samples were collected from patients
with ALL at the Hospital Civil Fray Antonio Alcalde.
Additionally, 19 blood samples from healthy donors
were collected as normal controls from the IMSS-Blood
Bank (Table 1). Each sample (5 mL) was collected with
EDTA as anticoagulant, mixed immediately after collec-
tion with 45 mL of RNA/DNA Stabilization Reagent for
Blood/Bone marrow (Roche Applied Science), and
stored at -80°C for conservation. From the stabilized
samples, we took a volume corresponding to 6 × 10
5
leukocytes for each patient or control and utilized this
for mRNA isolation via a two-step procedure through
magnetic separation employing the mRNA Isolation Kit
for blood/bone marrow (Roche Applied Science). mRNA
was finally eluted from the magnetic pearls in 20 μLo f
water and stored at -80°C until use.
cDNA synthesis
For cell lines, cDNA synthesis was performed from 5 μg
of total RNA. For patients or healthy volunteers, we
used the maximum volume of mRNA permitted in the
kit (8 μL). cDNA was obtained by using the Super-
Script™ III First-Strand Synthesis System primed with
oligo(dT) (cat. no. 18080051, Invitrogen). The protocol
was carried out as recommended by the manufacturers.
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Primers were designed using Oligo-Primer Analysis Soft-
ware, version 6.51 (Molecular Biology Insights, Inc., USA)
from sequences obtained from the GenBank Nucleotide
database of the NCBI website. Primers were synthesized
by Invitrogen Corporation, USA. The primers sequence,
the location of each primer, the gene symbol, the sequence
accession number, the amplicon length, and the annealing
temperature used are summarized in Table 2. The exten-
sion time used for each set of primers was set by dividing
the amplicon size by 25 sec, because the polymerase has
the capability to insert 25 bp per second.
Gene expression analysis was achieved by qRT-PCR
on the 1.5 LightCycler
® (Roche Diagnostics) using the
LightCycler-FastStart DNA MasterPLUS SYBR Green I
Kit (cat. no. 03515885001, Roche Applied Science) as
recommended by the manufacturers. A standard curve
with four serial dilution points and a negative control
were included in each run. Relative expression was cal-
culated with LightCycler software version 4.1 by taking
GAPDH, RPL32,o rRPS18 as reference genes.
Analysis in cell lines was performed by taking the
values obtained from two independent RNA extractions
in duplicate. In patients and healthy volunteers, experi-
ments were performed three times in each individual
sample.
In order to demonstrate that the reference genes
selected and used in our cell model were appropriate,
some samples were also tested with additional reference
genes, as shown in Additional File 1.
Δ CP analysis
For analysis of WNT7A expression in patients and in
healthy volunteers, we used ΔCP to facilitate analysis by
taking only intrinsic references from each sample. We
compared the ΔCP values obtained for both groups, i.e.,
the WNT7A CP minus the reference gene CP from the
same sample. GAPDH and RPL32 were used for normal-
ization in this analysis. It is very important to point out
that ΔCP is inversely proportional to the expression of
the target gene.
Isolation and culture of mononuclear cells
Peripheral blood mononuclear cells (PBMC) of healthy
volunteers were isolated by density gradient using
Ficoll-Paque PLUS (GE Healthcare, Sweden). Blood
with anticoagulant was diluted 1:1 in PBS without
MgCl2 and subsequently 1:1 in Ficoll-Paque PLUS.
After 30-min centrifugation at 1,500 rpm, the cells’ pel-
let was washed with PBS and resuspended in RPMI
medium complemented with 10% FBS and antibiotics.
Cells were led to growth at 37°C in an atmosphere of
5% CO2 in the presence or absence of phytohemaggluti-
nin (PHA - 2 μg/mL).
Treatment with WNT7a recombinant protein
Jurkat and PBMC were seeded at a density of 2 × 10
4
cells in a 96-well microtiter plate in 200 μLo fR P M I
medium. Recombinant human WNT7a (cat. no. 3008-
WN/CF, R&D Systems) was resuspended first in sterile
PBS and was afterward diluted 1:100 in the cell culture
medium. Every 24 h the recombinant protein was added
fresh to each well at a final concentration of 3 μg/mL;
incubations at 37°C were performed for 24 and 48 h.
Measurement of cell survival
After WNT7A overexpression or treatment with WNT7a
recombinant protein, cell survival was determined by
cleavage of tetrazolium salt WST-1 to formazan (cat.
no. 11 644 807 001, Roche Applied Science) by reading
the absorbance of treated and untreated cells at 440 nm
on a microtiter plate reader (Synergy™ HT Multi-Mode
M i c r o p l a t eR e a d e r .B i o t e k .W i n o o s k i ,V T ,U S A ) .T h e
value of untreated cells was used as 100% cell survival.
Table 1 Gender and Age of Control and Patients
Control ID Gender Age Patient ID Gender Age Diagnostic
1 M3 3 1 M 38 ALL
2 M2 6 2 M 82 ALL
3 F5 4 3 M 56 ALL
4 F3 4 4 F 46 ALL
5 F6 8 5 F 32 ALL
6 M5 1 6 F 36 ALL
7 F4 3 7 F 56 ALL
8 F2 4 8 M 84 ALL
9 F5 6 9 M 61 ALL
10 M4 0 10 M 58 ALL
11 F5 3 11 F 30 ALL
12 F3 5 12 M 52 ALL
13 F2 6 13 F 43 ALL
14 M3 9 14 M 18 ALL
15 M7 3 15 F 47 CLL
16 M4 5 16 F 31 CLL
17 F3 9 17 F 37 CLL
18 M4 0 18 F 58 CLL
19 M2 6 19 F 89 CLL
20 F 56 AML
21 F 82 AML
22 M 40 AML
23 M 55 AML
24 F 33 CML
25 M 35 CML
26 M 46 CML
Ochoa-Hernández et al. BMC Cancer 2012, 12:60
http://www.biomedcentral.com/1471-2407/12/60
Page 3 of 18Cloning WNT7A
WNT7A Open reading frame (ORF) (GeneID: 7476; NM
_004625) was amplified from human non-tumorigenic
keratinocytes utilizing the Expand High Fidelity PCR
System (cat. no. 11 732 650 001, Roche Applied Science)
with the following set of primers: forward 5’-GGG ACT
A T GA A CC G GA A AG C- 3 ’;r e v e r s e :5 ’- CGG GGC
TCA CTT GCA CGT GTA C -3’.A f t e r w a r d ,t h eP C R
product was cloned into the pCR2.1TOPO vector (Invi-
trogen). Construction was sequenced employing M13
Forward and Reverse primers (Invitrogen) with the Big-
Dye
® Terminator Cycle Sequencing Kit (Applied Biosys-
tems). After corroborating the WNT7A sequence with
that reported in GenBank, WNT7A ORF was isolated
from pCR2.1TOPO vector by EcoRI restriction and sub-
cloned into the EcoRI site of the lentiviral expression
vector pLVX-Puro or pLVX-Tight-Puro (Clontech
Laboratories, USA).
Lentivirus production and infection
To produce infectious viral particles, Lenti-X 293 T cells
were transient-transfected by the Lentiphos HT/Lenti-X
HT Packaging Systems with the lentiviral vectors pLVX-
Puro or pLVX-WNT7A-Puro as described by the manu-
facturers (Clontech Laboratories. USA). Tet-Express
Inducible Expression Systems were also used (pLVX-
Tet-On Advanced and pLVX-Tight-WNT7A-Puro).
After 48 h, supernatants were checked with Lenti-X
GoStix (Clontech Laboratories. USA) to determine
whether sufficient viral particles were produced before
transducing target cells. Supernatants were filtered
through a 0.45-μm PES filter to eliminate detached cells,
were aliquoted, and subsequently stored at -80°C until
use. Jurkat cells were transduced with 200 μLo fs u p e r -
natants obtained with pLVX-Puro or pLVX-WNT7A-
Puro. RNA and protein extractions were obtained after
2d a y so ft r a n s d u c t i o na n d1w e e ko fp u r o m y c i ns e l e c -
tion (1 μg/mL). Cell proliferation was also measured by
adding WST-1 to the culture cells at this point.
For inducible WNT7A expression in the leukemia-
derived cell lines, cells were first transduced with the
pLVX-Tet-On (regulator vector) and selected with G418
(cat. no. 631307, Clontech Laboratories, USA). After-
ward, cells were transduced with the pLVX-Tight-
WNT7A-Puro and selected with Puromycin for 2 weeks
(1.5 μg/mL). After selection, cells were grown in the
absence or presence of Doxycycline (Doxy) (750 ng/mL)
to overexpress WNT7A.
Western blot assays
Cells were harvested by scraping and were lysed with
RIPA buffer by sonication (15 pulses, 50% amp).
Extracts were incubated for 30 min at 4°C and obtained
by centrifugation (14,000 rpm for 5 min at 4°C). Protein
concentrations were determined using the Bio-Rad DC
Protein Kit (cat. no. 500-0114 Protein DC - BioRad,
Hercules, CA, USA) and 50 μgo fw h o l e - c e l le x t r a c t s
were electrophoresed in 12% SDS-PAGE. Proteins were
Table 2 Information of the oligonucleotides used for the qRT-PCR analysis
Gene Name Sequence Accession
Number
Primer Sequence Primer Location
(Exon
Prod.
Length
T°
a
WNT7A Wingless-type MMTV integration site family,
member 7A
NM_004625 F CAAAGAGAAGCAAGGCCAGTA
R GTAGCCCAGCTCCCGAAACTG
707-730 (3)
962-983 (4)
277 60
MYC V-myc myelocytomatosis viral oncogene
homolog (avian)
NM_002467.4 F CCAGCGCCTTCTCTCCGTC
R GGGAGGCGCTGCGTAGTTGT
1208-1226 (2)
1490-1509 (3)
302 60
JUN Jun proto-oncogene NM_002228.3 F TGGAAAGTACTCCCCTAACCT
R CTGAAACATCGCACTATCCTT
2786-2806 (1)
3015-3035 (1)
250 60
FRA-1 FOS-like antigen 1 NM_005438.3 F AGGAACCGGAGGAAGGAACTG
R TGCCACTGGTACTGCCTGTGT
554-574 (3)
732-752 (4)
199 60
AXIN2 Axin 2 NM_004655.3 F
AAAAAGGGAAATTATAGGTATTAC
R CGATTCTTCCTTAGACTTTG
2678-2701 (10/
11)
2935-2954 (11)
277 54
GAPDH Glyceraldehyde-3-phosphate
dehydrogenase
NM_002046.3 F CACTGCCACCCAGAAGACTGTG
R TGTAGGCCATGAGGTCCACCAC
645-666 (8)
1072-1089 (9)
449 63
RPL32 Ribosomal protein L32 NM_000994.3 F GACTTGACAACAGGGTTCGTAG
R ATTTAAACAGAAAACGTGCACA
213-234 (3)
511-532 (4)
320 60
RPS18 Ribosomal protein S18 NM_022551.2 F CGATGGGCGGCGGAAAA
R CAGTCGCTCCAGGTCTTCACGG
105-121 (2)
366-387 (5)
283 58
B2M Beta-2-microglobulin NM_004048.2 F GAGGCTATCCAGCGTACTCCAA
R CACACGGCAGGCATACTCAT
115-136 (1/2)
347-366 (2)
252 58
ACTB Actin beta NM_001101.3 F TCCGCAAAGACCTGTACG
R
AAGAAAGGGTGTAACGCAACTA
950-967 (5)
1226-1247 (6)
298 60
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and incubated with 1% Western blocking reagent (cat
no. 11921681001, Roche, Germany) to block nonspecific
binding. Primary antibodies were incubated over night
at 4°C and the secondary antibodies were incubated
with the membrane for 2 h at RT, followed by chemilu-
minescent detection using Immobilon Western substrate
(Millipore Corporation, USA) with the ChemiDoc XRS
(Biorad Laboratories, USA). The primary antibodies
used were: anti-b-Catenin (cat. no. SC-7199, Santa Cruz
Biotechnology, USA), anti-WNT7A (cat. no. AF3008
and cat. no. K-15, from R&D and Santa Cruz Biotech-
nology, respectively), or anti-b-Actin (cat. no. SC-26361,
Santa Cruz, Biothechnology).
Apoptosis detection
Cell death was measured by flow cytometry using propi-
dium iodide (cat. no. P4864, Sigma-Aldrich) and Annexin-
V-FLUOS (cat. no. 1828681, Roche Applied Science) as
recommended by these manufacturers. Cells were seeded
at a density of 2.5 × 10
5 cells per flask in 10 mL RPMI
medium with or without Doxycycline (750 ng/mL). After
a 72 h incubation, cells were washed with PBS and incu-
bated with Annexin and propidium iodide for 15 min;
10,000 events from each sample were analyzed in a FACS
Aria cytometer (BD Biosciences).
Statistical methods
Statistical analysis was performed with SPSS Statistics
software version 17.0. Post-hoc tests (Tukey HSD, Bon-
ferroni, and Dunnett 3 T) were utilized for multiple
comparisons between groups, and one-way ANOVA was
employed to compare the means among more than two
different groups. Only p values < 0.05 were considered
as significant.
Results
T-lymphocytes are the main cell population in peripheral
blood that expresses WNT7A
The expression of WNT7A in normal mature blood cells
is still not well characterized. From this starting point, we
wanted to know whether normal peripheral blood cells
express WNT7A and, more specifically, if T- or B-lym-
phocytes are expressing this Wnt ligand at the same
level. In order to address this goal, we obtained cDNA
from total blood cells, PBMC, T-lymphocytes (CD3
+
cells), and B-lymphocytes (CD19
+ cells)-positive cells.
CD3
+ and CD19
+ cells were sorted by Flow cytometry
( F C M )f r o mh e a l t h yv o l u n t e e r s ’ PBMC (Figure 1A).
Afterward, we determined the expression of WNT7A by
qRT-PCR in the groups mentioned previously utilizing
GAPDH, RPL32,a n dRPS18 as reference genes for rela-
tive expression analysis. Because efficiency and error of
reactions are important for relative quantification
analysis, standard curves obtained by serial dilutions (1:1,
1:2, 1:4, and 1:8) of cDNA were included in each PCR
(see Additional File 1). Only data from PCR reactions
showing an error < 0.04 and an efficiency of at least 1.8
were included in the analysis. Because CD3- and CD19-
sorted cells were isolated from PBMCs, we normalized all
values to those obtained in the PBMC. We found expres-
sion of WNT7A in total peripheral blood cells, but inter-
estingly, we observed approximately 84% lower WNT7A
expression in these cells than in PBMC (in which
WNT7A relative expression was set as 1) (Figure 1B).
Taking into account that 80% of peripheral blood cells
are from myeloid origin and that 80% of PBMC are lym-
phoid, we assume that myeloid cells are expressing very
low levels of WNT7A and that the main producers could
be lymphoid cells. To delve deeper into this question, we
analyzed the relative expression of WNT7A in pure CD3
+
and CD19
+ cells. We could determine that the highest
expression of WNT7A corresponds to CD3
+ cells; in con-
trast, CD19
+ cells express nearly undetectable levels of
this ligand. The WNT7A relative-expression difference
observed between PBMC and CD3
+ cells correlates with
the expected population’s percentage of T-lymphocytes
(~50-75%), B-lymphocytes (~10-25%), and NK cells (~5-
20%) in PBMC. Summarizing these data, WNT7A expres-
sion rises to the greatest degree from CD3
+ cells.
WNT7A expression is downregulated upon T-lymphocytes
activation
Given that peripheral CD3
+ (mature resting lymphocytes)
express WNT7A, we asked whether the expression of this
gene is related with their resting non-proliferative state.
To elucidate this question, PBMC were induced to prolif-
erate by addition of Phytohemagglutinin (PHA - 2 μg/mL),
a lectin molecule that preferentially induces T-lympho-
cytes proliferation. After 48 hours of PHA-treatment, total
RNA was isolated, retro-transcribed and analyzed by qRT-
PCR. As can be observed in Figure 2A, WNT7A mRNA
levels were drastically affected upon PHA activation,
decreasing from 1 (non-activated resting PBMC, control
cells) to 0.21 and 0.29 (relative expression ratio). Amplifi-
cation curves and melting peaks obtained for WNT7A,
RPL32,a n dRPS18 in non-treated PBMC and PHA-treated
PBMC are depicted in Additional File 2.
Reduced WNT7A gene expression levels in leukemia-
derived cell lines
Because WNT7A was expressed in resting peripheral T-
lymphocytes, but severely reduced in activated T-lym-
phocytes, we assumed that leukemia-derived cell lines
(which are undifferentiated and have a high grade of
proliferation) should express low levels of this ligand.
To test this hypothesis, we selected five different leuke-
mia-derived cell lines: two of lymphoid origin (Jurkat
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Page 5 of 18Figure 1 Expression of WNT7A in total peripheral blood cells, Peripheral blood mononuclear cells (PBMC), sorted CD3
+ and CD19
+
cells obtained from healthy volunteers’ samples. (A) Dot blot graphics showing the selected region for sorting (upper left panel), CD3-
Fluorescein isothiocyanate (FITC), and CD19-Phycoerythrin (PE) marked cells (upper right panel), isolated CD19
+ cells (lower left panel), and
isolated CD3
+ cells (lower right panel). (B) Figure showing the average of the WNT7A relative expression ratio ± Standard deviation (SD) obtained
from the different groups. Normalization was performed by setting CP values of PBMC as 1 and taking GAPDH, RPL32, and RPS18 as reference
genes. Experiments were carried out at least twice in all cases.
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Page 6 of 18and CEM); two of myeloid origin (K562 and HL60), and
a lymphoma-derived B cell line (BJAB). We included
also myeloid immature cell lines to determine whether
this myeloid lineage indeed (as previously calculated by
the analysis obtained from peripheral blood volunteer’s
samples) expresses very low levels of WNT7A.
Therefore, we determined the quantitative expression of
WNT7A by qRT-PCR assays. As a reference for compar-
ison, we also included in this analysis a mix of cDNA
obtained from total peripheral blood cells of five clini-
cally healthy volunteers (control group). As can be
observed in Figure 2B, relative expression utilizing
Figure 2 Relative expression of WNT7A in control cells and leukemia-derived cell lines. (A) Relative expression levels of WNT7A
determined by qRT-PCR in resting and phytohemagglutinin-activated PBMC (activation was performed in PBMC from two volunteers and named
TxPHA 1 and TxPHA 2). Values of the resting PBMCs (Control) of both volunteers were set as 1. (B) Relative expression levels of WNT7A
determined by qRT-PCR in Jurkat, CEM, K562, HL60, and BJAB cell lines normalized to the healthy volunteers control group (setting as 1). In A,
quantification was calculated using, Ribosomal Protein L32 (RPL32) and Ribosomal Protein S18 (RPS18) as reference genes. In B, quantification was
calculated using additionally Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The graphics show means obtained with both reference
genes and Standard deviations (SD). Experiments were carried out at least twice in duplicate.
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very low expression levels of WNT7A in all leukemia-
derived cell lines when compared with the control
group. We observed relative values ranging from 0.026
in Jurkat cells to 0.002 in K562 cells when normalized
to the control group (set as 1). After qRT-PCR assays,
all amplified products were resolved in 1.5% agarose
gels and visualized with Ultraviolet (UV) light for photo-
documentation (data not shown).
In conclusion, the experiments performed previously
allow us to demonstrate quantitatively that leukemia-
derived cell lines of both myeloid and lymphoid origins
express very low levels of WNT7A.
Peripheral blood cells of patients with leukemia also
showed a significant decrease in WNT7A gene expression
After demonstrating that WNT7A expression is strongly
reduced in leukemia-derived cell lines, we wanted to
determine whether WNT7A expression could also be
diminished in blood samples of patients with leukemia
in comparison with clinically healthy volunteers. With
this aim, the expression of WNT7A was analyzed in 14
samples of patients with Acute lymphoblastic leukemia
(ALL) and in 19 samples of clinically healthy volunteers.
We decided to determine the expression of WNT7A by
normalizing to an internal reference gene; thus, the ΔCP
was calculated, which represents a more absolute value.
It is noteworthy that the ΔCP (CP of target gene - CP
of reference gene) is inversely proportional to the
expression of the target gene. Values of ΔCP of the ana-
lyzed groups (control and ALL) are represented in box
plot graphics in Figure 3A. As can be observed in this
figure, there is an evident difference between control
values and those of patients with ALL normalized either
with GAPDH (left panel) or with RPL32 (right panel).
Higher ΔCP values were observed in the ALL group,
which means lower expression of WNT7A. As shown in
Figure 3A, when we compared the ALL group vs. the
healthy volunteers group, we observed a statistical sig-
nificance of p < 0.001 when normalized with GAPDH
and p <0 . 0 0 3w i t hRPL32. These results permit us to
suggest that reduction of WNT7A expression could be a
characteristic hallmark in patients with ALL.
Taking the median of the ΔCP values of controls and
patients with ALL obtained with both reference genes,
we calculated the average of WNT7A relative expression.
As can be observed in Figure 3B, the average of WNT7A
expression in patients in comparison to the control
g r o u p( s e ta s1 )d i m i n i s h e dt o0 . 0 4 3( GAPDH)o rt o
0.135 (RPL32).
In summary, there is a statistically significant
decreased expression of WNT7A, not only in leukemia-
derived cell lines in comparison with the control group,
but also in patients with ALL when compared with
healthy volunteers. Peripheral blood cells from four
Acute myeloid leukemias (AML), three Chronic myeloid
leukemia (CML), and five Chronic lymphocytic leukemia
(CLL) also revealed a tendency to exhibit reduced
WNT7A expression when compared with the control
group (data not shown).
Restoration of WNT7A inhibits cell growth in Jurkat cells
Because we found that WNT7A is expressed in CD3
+
resting lymphocytes derived from healthy volunteers and
not in immature leukemia-derived cells, it was in our
interest to discern the biological effect of WNT7a
restoration on leukemia cells. For this purpose, we used
lymphoblastic Jurkat cells as model and overexpressed
WNT7A employing a lentiviral system (pLVX-Puro or
pLVX-WNT7A-Puro; a detailed description is provided
in Materials and Methods). After 48 h of infection, cells
were cultured with 1 μg/mL puromycin for selection of
infected cells, and RNA and protein extraction were
conducted on day 7 to corroborate WNT7A overexpres-
sion by qRT-PCR and Western blot assays (Figure 4).
After this selection time, WNT7A relative expression
was measured in the pLVX empty-vector infected cells
and in the pLVX-WNT7A clone 1- and -2-infected
cells. We named these cells clone 1 and clone 2 because
we infected Jurkat cells with the viral particles contain-
ing pLVX-WNT7A-Puro in two independent experi-
ments. As can be observed in Figure 4A, expression of
WNT7A in pLVX-WNT7A infected cells was increased
nearly 27-fold when compared to the pLVX-empty vec-
tor. The amplified products from the qRT-PCR assays
were also electrophoresed on 1.5% agarose gel as
depicted in Figure 4B. Additionally, as can be observed
in Figure 4C, WNT7A overexpression was also con-
firmed at protein levels.
To determine the biological effect of WNT7A restora-
tion in cell proliferation, after 2 weeks puromycin selec-
tion, we seeded in the same number (10,000) of Jurkat,
Jurkat-pLVX, and Jurkat-pLVX-WNT7A cells in 96-well
plates and measured the percentage of cell proliferation
after a 48 h culture. Percentages of cell proliferation were
obtained by taking the Optical density (OD) values of
Jurkat cells as 100%. As illustrated in Figure 5A, we
observed a decrease in the rate of cell proliferation of Jur-
kat-pLVX cells (91.87%), but a significantly lower
decrease was observed in Jurkat-pLVX-WNT7A cells
(49.84%). This observation allowed us to speculate that
the WNT7A produced by Jurkat-infected cells could
somehow inhibit cell proliferation. To discern this point,
Jurkat cells and resting PBMC obtained from one of the
healthy volunteers were incubated with 3 μg/mL of com-
mercially recombinant human WNT7a for 48 h. As can
be observed in Figure 5B, incubation of Jurkat cells with
recombinant human WNT7a (rhWNT7a) reduced their
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PBMC exhibited only a small effect, even reaching
79.02% of growth at 48 h.
Restoration of WNT7A does not induce the canonical
b-catenin pathway in Jurkat cells
To determine whether the proliferation inhibition in
Jurkat cells observed after WNT7a restoration was
mediated by activation of the canonical b-catenin path-
way, we analyzed the expression of putative target genes
for this pathway by qRT-PCR assays. For this purpose,
we determined the mRNA expression of AXIN2, MYC,
JUN,a n dFRA-1 in Jurkat-pLVX- and Jurkat-pLVX-
WNT7A-infected cells clone 1 and 2. As can be appre-
ciated in Figure 6A, none of the aforementioned genes
was activated by WNT7A restoration. Instead, decreased
expression in JUN and FRA-1 was observed in clones
expressing WNT7A. Interestingly, when we incubated
cells with LiCl (0.01 M) for 20 h (it is known that LiCl
activates Wnt signaling by inhibiting GSK3b, leading to
b-catenin stabilization and translocation into the
nucleus [25,26]), a restoration of the expression levels of
JUN and FRA-1 was observed, which indicates that LiCl
antagonize WNT7A activity in these cells (see Figure
6B). Additionally, to support that WNT7a in this model
did not induce the canonical pathway, we performed
Western blot assays to detect b-catenin in Jurkat, Jur-
kat-pLVX, and Jurkat-pLVX-WNT7A cells. As control,
we also included LiCl-treated Jurkat cells. As expected,
accumulation of b-catenin was only observed in the
LiCl-treated cells and not in the WNT7A expressing
cells (Figure 6C). These results clearly support the idea
that the canonical pathway is not involved in the action
of WNT7A on Jurkat cells.
Restoration of WNT7A inhibits cell growth in K562, BJAB,
and CEM cells
T oc o n f i r mt h a tr e s t o r a t i o no fWNT7A inhibits cell
growth in leukemia-derived cells, we modified K562,
BJAB, and CEM cells to overexpress WNT7A employing
an inducible-lentiviral expression system (as described
in Methods). We first obtained K562-, BJAB-, and
CEM-Tet cells that contained only the regulator vector
( T e t ) .N e x t ,w eo b t a i n e dK 5 6 2 - ,B J A B - ,a n dC E M - T e t -
WNT7A cells that should express WNT7A in the pre-
sence of doxycycline. To verify WNT7A overexpression,
K562-, BJAB-, and CEM-Tet-WNT7A cells were grown
in the absence or presence of doxycycline (750 ng/mL)
for 4 h. Afterward, RNA extraction and retrotranscrip-
tion were performed for the qRT-PCR assays. As can be
observed in Figure 7A, expression of WNT7A indeed
increased in all cell lines, rising 7.48 ± 1.19-fold in
Figure 3 WNT7A expression in immature cells from patients with Acute lymphoblastic leukemia (ALL). (A) Box plot graphics showing
ΔCP values taking GAPDH (left panel) or RPL32 (right panel) as reference genes. The graphics display median (dark lines), 25-75th percentile
(boxes), interquartile ranges (whiskers), and outliers (small, dark circles) from 14 patients with ALL. Peripheral blood cells from 19 controls were
included for comparison. Statistical significances are shown between both groups. (B) Graphic showing an average of the relative expression
levels of WNT7A from the control and from the group with patients with ALL. The value obtained in the healthy volunteers control group was
set as 1 and normalized either with GAPDH or RPL32 as reference genes.
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Page 9 of 18Figure 4 WNT7A overexpression in Jurkat cells. Overexpression of WNT7A in Jurkat cells using the lentiviral system was confirmed by qRT-
PCR assays. (A) Graphic showing WNT7A relative expression taking GAPDH, RPL32 and RPS18 as constitutive genes in cells infected with pLVX
(vector alone) or with pLVX-WNT7A. Infection was carried out in duplicate (pLVX-WNT7A clone 1 and 2). (B) Amplification products of WNT7A
and RPS18 were run in 2.0% agarose gels and photodocumented. (C) Western blot assays (from 50 μg total protein) showing the presence of
WNT7a protein only in pLVX-WNT7A-infected cells. The magic mark (2 μl) was used as protein marker.
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CEM. This induced overexpression was also confirmed
at protein levels (after 48 h of doxycycline exposure) by
Western blot analysis (see in Figure 7B).
Once we could establish that our inducible-WNT7A
system was working adequately, we determined the
WNT7A restoration effect on cell proliferation. For this
purpose, we added WST-1 to the culture cells growing
in the presence or absence of doxycycline after 24 and
48 h of incubation. Percentages of cell proliferation were
obtained by taking the OD values of the cells growing in
the absence of doxycycline as 100% of cell proliferation.
A sm a yb es e e ni nF i g u r e8 ,W N T 7 A -inducible expres-
sion in all three cell lines decreased strongly, especially
in BJAB-Tet-WNT7A and in CEM-Tet-WNT7A cells,
decreasing to 40.62 and 38.77%, respectively, after 48 h
of growth in the presence of doxycycline.
Discussion
Wnt signaling is conserved from invertebrates to verte-
brates and regulates early embryonic development, as
well as the homeostasis of adult tissues; as a central
Figure 5 WNT7A inhibits cell proliferation in Jurkat cells. (A) Percentage of cell proliferation measured in Jurkat cells, Jurkat-pLVX (stable
transduced with empty-vector), or Jurkat-pLVX-WNT7A cells after 48 h of culture. Percentages of cell proliferation were obtained by taking
Optical density (OD) values of the Jurkat cells as 100% cell proliferation. (B) Leukemia-derived Jurkat cells and PBMC were exposed for 48 h to 3
μg/mL of recombinant human WNT7a (+rhWNT7a). Afterward, the percentage of cell proliferation was measured by employing WST-1 and
setting the value of non-treated control cells (Jurkat and PBMC for their respective assays) at 440 nm as 100% of cell proliferation.
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Page 11 of 18Figure 6 Restoration of WNT7A does not induce the canonical b-catenin pathway in Jurkat cells. (A) Relative expression levels of AXIN2,
MYC, JUN, and FRA-1, determined by qRT-PCR in Jurkat-pLVX or Jurkat-pLVX-WNT7A clone-1 and -2 infected cells. Quantification was calculated
by normalizing with Jurkat-pLVX (setting as 1) and utilizing GAPDH and RPL32 as reference genes. The graphic shows medians obtained with
both reference genes ± Standard deviations (SD). (B) Relative expression levels of AXIN2, MYC, JUN, and FRA-1, determined by qRT-PCR in Jurkat-
pLVX or Jurkat-pLVX-WNT7A clone-1 in the absence or presence of LiCl. Quantification was calculated by normalizing LiCl-treated cells with their
corresponding Jurkat-pLVX or Jurkat-pLVX-WNT7A non-treated cells (setting each as 1) and utilizing GAPDH and RPL32 as reference genes. The
graphic shows medians obtained with both reference genes ± SD. (C) Western blot analysis detecting b-catenin and b-actin in the presence or
absence of LiCl and WNT7a.
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of Wnt signaling is associated with many human dis-
eases, and particularly with cancer [1]. Recently, Wnt
signaling has also been implicated in hematopoiesis,
both in self-renewal and in differentiation [1,10,18].
Based on these observations, it is hypothesized that dys-
regulation of the WNT pathway might contribute to the
pathogenesis of lymphoproliferative diseases [12].
Despite the modest number of reports on the poten-
tial roles of Wnt signaling in leukemia, it is increasingly
clear that Wnt signaling is dysregulated in several types
of leukemia [12,18,27]. Some of these findings involve
over- or underexpression of several Wnt ligands or
Frizzled receptors [16,19,28,29], hypermethylation of
natural WNT inhibitors [30], and overexpression of b-
catenin [21].
Despite this knowledge, there are a very limited num-
ber of publications on the expression of WNT7A and its
role in the biology of blood cells. One of the first obser-
vations of the implication of WNT7A in hematological
disorders was the frequent deletion of the 3p25 chromo-
some band observed in patients with AML, CML, and
Figure 7 WNT7A overexpression in K562-, BJAB- and CEM-Tet-WNT7A cells.O v e r e x p r e s s i o no fWNT7A in these cell lines using the
doxycycline-inducible lentiviral expression system was confirmed by qRT-PCR and Western blot assays. (A) Graphics showing the amplification
curves obtained for WNT7A and RPL32 in cells treated or not with Doxycycline (Doxy) for 4 h. The WNT7A normalized relative ratio of the cells
treated with Doxy was calculated utilizing the non-treated cells as calibrator and taking GAPDH, RPL32 and RPS18 as reference genes in two
independent experiments. (B) Western blot assays (from 50 μg total protein) showing the presence of WNT7a protein after a 38-h incubation
with Doxy. Photo-documentation of the Coomassie stained gel is included as protein loading control.
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chromosomal region [32,33] and its deletion could be
an important step during the neoplastic transformation.
In this paper, we report the expression of WNT7A in
normal peripheral T-lymphocytes and strongly reduced
WNT7A expression, not only in leukemia-derived cell
lines, but also in the peripheral blood cells of patients
with leukemia.
We were able to demonstrate that T-lymphocytes, but
not B-lymphocytes, express WNT7A (ΔCP 11.47 ± 1.2).
Figure 8 Restoration of WNT7A in K562-, BJAB-, and CEM-Tet-WNT7A cells inhibits their cell proliferation.G r a p h so ft h el e f tc o l u m n
depict the percentage of cell proliferation measured in K562-, BJAB-, and CEM-Tet-WNT7A cells after 24-h and 48-h incubation with Doxycycline
(Doxy). The empty-vector cell lines (K562-, BJAB-, and CEM-Tet) were also included as controls. The percentage of cell proliferation was measured
by adding WST-1 to the cell cultures for 2 h and by reading the absorbance of treated and untreated cells at 440 nm. The value in each cell line
of non-treated cells after 24 or 48 h was setting as 100% of cell proliferation. Right column graphs illustrate the histograms of the flow-
cytometric analysis done for apoptosis detection utilizing Annexin-V-FLUOS as markers in non-treated (filled curve) and 48-h Doxy-treated cells
(open curve). Ordinate: number of cells; Abscissa: fluorescence intensities.
Ochoa-Hernández et al. BMC Cancer 2012, 12:60
http://www.biomedcentral.com/1471-2407/12/60
Page 14 of 18In agreement with this observation, Lu et al. also found
expression of this ligand in peripheral blood lympho-
cytes (ΔCP 11.81 ± 0.99), but do not determined that
this expression was afforded mainly from T-cells [19]. In
contrast, Sercan et al. found WNT7A expression in both
T- and B-cells obtained from healthy volunteers [23].
Discrepancies in these data could be due to the different
method employed for quantification. The previously
mentioned research group quantified WNT7A expres-
sion by comparing the densities of amplified WNT7A
and b-actin PCR products visualized on agarose gels,
while our group did this by performing qRT-PCR assays,
which afford very precise data for quantification analysis.
We found from 38- to 500-fold lower expression in
leukemia-derived cell lines than in healthy control cells
(see Figure 2B). These results are in agreement as
reported recently by Sercan et al., in which they did not
find WNT7A expression in leukemia-derived cell lines
K562, HL60, Jurkat, and Namalwa [23]. However, the
authors measured qualitatively, while we determined
WNT7A expression quantitatively.
On the other hand, expression of WNT7A in hematolo-
gical diseases has been only determined in patients with
CLL and AML. Memarian et al. observed reduced expres-
sion of WNT7A in Iranian patients with AML compared
with normal subjects [24]; however, the authors did not
find this difference in patients with CLL [29]. It is note-
worthy that in both of these previously mentioned
reports, WNT7A expression was calculated using the
band densities of WNT7A and b-actin after conventional
PCR. In agreement with the results of Memarian et al. we
also observed reduced expression of WNT7A also in
patients with AML, but statistical significance was not
reached, probably due to the low number of patients with
AML whom we analyzed (data not shown). Regarding
expression of this ligand in patients with CLL; Lu et al.
also observed lower WNT7A expression in patients with
CLL (ΔCP 15.43 ± 2.94) when compared with healthy
peripheral blood lymphocytes (11.81 ± 0.99)[19]. In this
sense, we also observed this behavior in 4 out of 5 CLL
patients (ΔCP 16.3 ± 1.5). Despite this low number of
CLL patients, we found a statistical significance of p
≤0.02 when compared with healthy control cells (ΔCP
11.47 ± 1.2) (data not shown).
Interestingly, when we analyzed peripheral blood cells
from 14 patients with ALL, these also expressed reduced
WNT7A expression (ΔCP 15.19 ± 2.5) and we found a
statistically significant difference of p ≤0.001 (GAPDH)
and p ≤0.003 (RPL32)w h e nc o m p a r e dw i t ht h ec o n t r o l
group (Figure 3).
Another important observation that we discerned is
that WNT7A decreases acutely after PHA activation. To
our knowledge, this is the first report evidencing that
lymphocytes require reduction of their WNT7A levels in
order to proliferate and suggests that dysregulation in
the expression of this ligand needs to occur during
oncogenesis to lose control of cell proliferation. Interest-
ingly, it has been reported that T-cell activation by phy-
tohemagglutinin results in a strong increase of
phosphorylated GSK3b [34], which in turn targets beta-
catenin for ubiquitylation and proteasomal degradation
[35].
With respect to the reference genes used in the qRT-
PCR assays, it is important to mention that there are no
perfect reference genes for every treatment in every cell
line. Thus, we used at least two reference genes in each
assay and also evaluated some samples with a total of
five reference genes (please see Additional Files 1 and
2). It has been determined that one of the reference
genes that we used (RPS18) is useful as internal control
for quantitative PCR in human lymphoblastoid cells,
because constant levels of expression across the cell
lines used were found following exposure to ionizing
radiation as well as to PHA [36]. However, it could be
that some, but not all, of the changes in WNT7A
expression may be caused by changes in reference-gene
expression when cells were treated with PHA.
To our knowledge, no other papers relating WNT7A
and leukemia have been published; however, reduced or
absent expression of WNT7A has also been observed in
lung cancer when compared with normal lung and mor-
tal, short-term bronchial epithelial culture by qRT-PCR
assay [36,37].
Furthermore, it has been reported that WNT7a acti-
vates E-cadherin expression in lung cancer cells and
that WNT7A loss may be important in lung cancer
development or in progression due to its effects on E-
cadherin, because E-cadherin in cancer has been asso-
ciated with dedifferentiation, invasion, and metastasis
[38]. In addition to the role of WNT7A observed in leu-
kemia and lung cancer, disruptions or alterations of the
WNT7A gene have also been found in oral premalignant
lesions [39] and in esophageal squamous cells [40].
We were also able to demonstrate, in the Jurkat leuke-
mia-derived cell line, that restoration of WNT7A (by lenti-
viral overexpression or the addition of human recombinant
protein) inhibits cell proliferation (Figure 5). Moreover,
with the inducible-lentiviral overexpression system, we also
confirmed this observation in K562, BJAB, and CEM cells
after WNT7a expression; however, induction of cell death
was not observed (Figure 8). Spinsanti et al. also reported
an anti-proliferative action of WNT7a expression in undif-
ferentiated PC12 cells [41]. Additionally, recent studies
have demonstrated that the combined expression of
WNT7A and Frizzled 9 (Fzd9) in Non-small cell lung
cancer (NSCLC) cell lines inhibits transformed growth by
activating ERK5 and increasing PPARgamma activity,
representing a novel tumor suppressor pathway in lung
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action in cancer is controversial at present; some evidence
supports its activity as an oncogene, but there is also evi-
dence of its tumor suppressor action [36,44,45]. This dual
role can be explained by the FZD proteins that bind
WNT7a. It has been reported that the binding of WTN7a
and FZD5 induces the canonical pathway, which has been
related with cancer development [46,47]. On the other
hand, WTN7a can also bind FZD-10 and -9, which in turn
activated the c-Jun NH2-terminal kinase pathway (JNK).
Activation of JNK has been shown to antagonize the cano-
nical pathway [47].
Due to the reported dual behavior of WNT7A as a
cell-proliferation inducer or blocker, it is reasonable to
think that Jurkat cells preferentially express anti-prolif-
erative FZD partners of WNT7A. To address this ques-
tion, we analyzed the presence of FZD mRNAs in Jurkat
cells compared with T-lymphocytes from healthy con-
trols and found overexpression of FZD-3 and -6 and
downmodulation of FZD-5 and -10 in Jurkat cells (data
not shown). On analyzing hematopoietic cells and leuke-
mia-derived cells, Sercan et al. also found expression of
FZD-3 and -6 in leukemia-derived T-lymphocytes [23].
The presence of FZD-6 in lymphocytes is interesting,
because it has been shown that FZD-6 can act as a
negative regulator of the canonical pathway [48].
Whether FZD-6 can interact with WTN7a in lympho-
cytes and what the biological consequences of this inter-
action would be are questions that remain open.
It has been observed that increased expression of
some WNT ligands such as WNT3a, induces activation
of the canonical pathway, accompanied by an increase
in the proliferation and survival of leukemia cells [49].
In addition, it has been reported that b-catenin com-
prises an integral part of AML cell proliferation and cell
cycle progression [50]. Because we observed downmodu-
lation of WNT7A in leukemia-derived cells, it appears
that WNT7a in Jurkat cells does not activate the WNT/
b-catenin pathway. Evidence that supports this notion is
the finding that mRNA levels of the putative canonical
target genes AXIN2, MYC, JUN,a n dFRA-1 were not
increased after WNT7a restoration (see Figure 6). In
contrast, mRNA from JUN and FRA-1 were strongly
downregulated in WNT7A-expressing cells, but again
restored (FRA-1) or even upregulated (JUN)w h e nc e l l s
were treated with LiCl (Figures 6A &6B). Concerning
this point, it has been reported that the b-catenin - T
cell-factor/lymphoid-enhancer-factor complex directly
interacts with the promoter region of JUN and FRA-1
[51]. Because we observed restoration of the expression
levels of JUN and FRA-1 after LiCl treatment, it is very
probable that LiCl antagonize WNT7a activity in these
cells. An additional observation that supports the idea
that WNT7a is working in this model in a non-
canonical pathway is that expression of b-catenin was
not increased after WNT7a restoration (as seen in
Figure 6C).
Conclusions
In conclusion, we are demonstrating, by qRT-PCR ana-
lysis, that WNT7A is significantly reduced in leukemia-
derived cell lines as well as in patients with leukemia
when compared with clinically healthy volunteers. The
finding that WNT7A restoration inhibits proliferation of
leukemia-derived Jurkat cells, but not of PBMC, allows
us to assume that WNT7A can be acting as a modulator
of cell proliferation, especially in T-cells that are produ-
cing this protein. In this regard, impairment of this anti-
proliferative function could be an important event in
leukemia and in some cancer-cell types. If this is true,
therapeutic tools directed toward restoring WNT7A
expression in patients with leukemia might increase the
probabilities of their overcoming this disease.
Additional material
Additional_file_ 1: Relative expression analysis comparison among
five of the most used reference genes. A panel of five different
reference genes was used to calculate WNT7A expression. Amplification
curves of all genes are shown in BJAB cells treated or not with
Doxycycline (+Doxy). Standard curves were performed to calculate error
and efficiency in all genes used. Table show WNT7A relative expression
normalized with the different reference genes.
Additional_file_ 2: Amplification curves obtained in cells treated or
not with PHA. Upper panel graphics shown the Amplification curves
obtained for WNT7A in non-treated PBMC and in PBMC treated for 48 h
with PHA. Middle graphics correspond to RPS18 and bottom panel
graphics to RPL32. Melting peaks are also shown in the right panels,
which indicate the specificity of the PCR reaction.
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